Overview
| Product name | Recombinant Human Mature BMP-7 Protein |
|---|
| Catalog No. | RP02513S |
|---|
| Description | Recombinant Human BMP-7 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ser293-His431) of Human BMP-7(Accession #NP_001710.1) fused with His tag at the N-terminus |
|---|
| Bio-Activity | Measured by its ability to induce alkaline phosphatase production by ATDC5 mouse chondrogenic cells.The ED50 for this effect is 34.9-139.58 ng/mL, corresponding to a specific activity of 7.2×103~2.87×104 units/mg.
|
|---|
| Purity | > 95% by SDS-PAGE. |
|---|
| Endotoxin | < 0.1 EU/μg of the protein by LAL method. |
|---|
| Formulation | Lyophilized from a 0.22 μm filtered solution of 50mM acetic acid，pH3.6. |
|---|
| Species | Human |
|---|
| Calculated MW | 15.68 kDa |
|---|
Background
BMP-7 (Bone morphogenetic protein 7) is a bone morphogenetic protein which belongs to the TGF-β superfamily. OP-1 is expressed in the brain, kidneys, and bladder. BMP-7 may be involved in bone homeostasis and plays a key role in the transformation of mesenchymal cells into bone and cartilage. The phosphorylation of SMAD1 and SMAD5 can be induced by BMP-7, which in turn induce transcription of numerous osteogenic genes. BMP-7 treatment can also induce all of the genetic markers of osteoblast differentiation in many cell types. Human recombinant BMP-7 protein can be used to aid in the fusion of vertebral bodies to prevent neurologic trauma. It also functions in the treatment of tibial non-union, frequently in cases where a bone graft has failed. It is found that BMP7 has the potential for treatment of chronic kidney disease.
Product information
| Synonym | BMP7; OP1; Bone morphogenetic protein 7; BMP-7; Osteogenic protein 1; OP-1; Eptotermin alfa |
|---|
| Expression Host | HEK293 cells |
|---|
| Tag | No-Tag |
|---|
| Swiss-Prot | |
|---|
| Gene ID | |
|---|
Usage guide
| Storage | Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. |
|---|
| Reconstitution | Centrifμge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. |
|---|
* For research use only. Not for therapeutic or diagnostic purposes.
